Preparation method and application of polyaspartic acid chelated zinc

Polyaspartate/ammonium copolymer aqueous solution is prepared by using sodium hydroxide or potassium hydroxide, ammonia water and polysuccinimide in cosmetics and reacting with water-soluble zinc salts, polyaspartate in the prior art is solved The complex preparation process of ammonic acid chelating zinc and the low zinc chelation rate have achieved efficient and environmentally friendly preparation of zinc chelation, which is suitable for moisturizing, whitening and anti-inflammatory effects in cosmetics.

CN119039600AActive Publication Date: 2024-11-29YOURAN INNOVATION (BEIJING) TECHNOLOGY R&D CENTER CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411160220.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-11-29
Estimated Expiration
2044-08-22

AI Technical Summary

Technical Problem

The existing preparation process of polyaspartic acid chelated zinc is complex and the conditions are harsh. The zinc chelation rate is low, making it difficult to meet the needs of cosmetics' effective ingredients.

Method used

Prepare a aqueous solution of sodium aspartate/ammonium copolymer by sodium hydroxide or potassium hydroxide, ammonia water and polysuccinimide. After adjusting the pH value, react with water-soluble zinc salt under mild conditions, and passes membrane filtration and electrodialysis. The impurities were removed to obtain a polyaspartic acid chelated zinc aqueous solution with a high chelation rate.

Benefits of technology

It achieves a high chelation rate of zinc (more than 99%) and low free zinc ion content. It has a simple process, environmentally friendly and relatively low cost. It is suitable for moisturizing, whitening and anti-inflammatory applications in cosmetics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119039600A_ABST
    Figure CN119039600A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method and application of polyaspartic acid chelated zinc, and the preparation method comprises the following steps: dissolving sodium hydroxide or potassium hydroxide in deionized water, dropwise adding ammonia water, fully and uniformly mixing, adding polysuccinimide, stirring for dissolving, and filtering to obtain polyaspartic acid chelated zinc; carrying out suction filtration to obtain a sodium / ammonium polyaspartate copolymer or potassium / ammonium polyaspartate copolymer aqueous solution; adjusting the pH value of the sodium / ammonium polyaspartate copolymer aqueous solution or the potassium / ammonium polyaspartate copolymer aqueous solution to 4.5-6.5 by adopting an inorganic acid aqueous solution, adding a water-soluble zinc salt, and continuously and fully stirring in a water bath to obtain a product solution; soluble impurities in the product solution are removed, and the final product polyaspartic acid chelated zinc aqueous solution is obtained. According to the polyaspartic acid chelated zinc prepared by the method, the chelating rate of zinc is relatively high, free zinc ions are few, the reaction condition is mild, and the method is simple.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of daily chemical products, and in particular to a preparation method and application of polyaspartic acid chelated zinc. Background Art

[0002] Zinc is one of the essential trace elements for the human body and plays an extremely important role in the growth and development of the human body. Its content in the human body is second only to iron. In skin care, zinc can be beneficial to improving acne. It participates in histone deacetylation, maintains the function of macrophages, neutrophils, natural killer cells and complement activity, stabilizes organelle membranes, and reduces the production of inflammatory mediators. Zinc can also block ultraviolet rays, has antioxidant effects, and can promote the absorption of antibiotics.

[0003] Polyaspartic acid and its sodium salt have excellent moisturizing properties. In addition, it has a strong hydrating function, which can improve the moisture of the skin. It has an efficient water-locking and moisturizing function, making the skin smooth and refreshing. It can also replenish skin nutrition and improve the fullness and elasticity of the skin.

[0004] Therefore, polyaspartate chelated zinc can increase the anti-inflammatory and whitening effects on the basis of the moisturizing properties of polyaspartic acid and its sodium salt; and compared with elemental zinc, zinc oxide and zinc salt, the relative stability of its chelate bond effectively improves the durability of its efficacy.

[0005] Existing polyaspartate chelated zinc is mostly used in feed or fertilizer, which is obtained by multi-step reaction with zinc oxide or zinc hydroxide as raw material. These processes have many control factors, harsh conditions, and the zinc chelation rate in the product is relatively low. Therefore, it is necessary to develop a preparation process for polyaspartate chelated zinc with simple preparation process, fewer steps, and higher zinc chelation rate in the product to meet the demand as a cosmetic functional ingredient. Summary of the invention

[0006] (I) Purpose of the invention

[0007] The invention aims to provide a preparation method and application of polyaspartic acid chelated zinc. The polyaspartic acid chelated zinc prepared by the method has a high zinc chelation rate and few free zinc ions. The chelation process uses water as a solvent for homogeneous reaction, the reaction conditions are mild, and the method is simple, efficient and environmentally friendly.

[0008] (II) Technical solution

[0009] In order to solve the above problems, the first aspect of the present invention provides a method for preparing polyaspartic acid chelated zinc, comprising:

[0010] S1, dissolving sodium hydroxide or potassium hydroxide in deionized water, adding aqueous ammonia dropwise and mixing thoroughly, adding polysuccinimide, stirring to dissolve, and filtering to obtain a sodium polyaspartate / ammonium copolymer aqueous solution or a potassium polyaspartate / ammonium copolymer aqueous solution;

[0011] S2, using an inorganic acid aqueous solution to adjust the pH of the sodium polyaspartate / ammonium copolymer aqueous solution or the potassium polyaspartate / ammonium copolymer aqueous solution to 4.5-6.5, adding a water-soluble zinc salt, and continuing to fully stir in a water bath at 60-80° C. to obtain a product solution;

[0012] S3, separating and removing soluble impurities in the product solution to obtain a final product, a polyaspartate chelated zinc aqueous solution.

[0013] Furthermore, in S1, the polysuccinimide is obtained by polymerization of aspartic acid, and the average molecular weight of the polysuccinimide ranges from 3 to 50 kDa.

[0014] Furthermore, in S1, the molar ratio of the ammonia water, the sodium hydroxide or potassium hydroxide, and the polysuccinimide repeating unit is x:1:y, wherein 0.05≤x≤0.2, 0.8≤y≤1, and the polysuccinimide is composed of polysuccinimide repeating units.

[0015] Furthermore, in S1, the mass fraction of the sodium polyaspartate / ammonium copolymer aqueous solution or the potassium polyaspartate / ammonium copolymer aqueous solution is 3wt% to 30wt%.

[0016] Furthermore, the method for separating and removing soluble impurities in the product solution in S3 includes membrane filtration and electrodialysis.

[0017] Furthermore, the water-soluble zinc salt includes zinc chloride, zinc sulfate, zinc nitrate, zinc acetate, zinc lactate, zinc gluconate and zinc aspartate.

[0018] Furthermore, in S2, the molar ratio between zinc in the water-soluble zinc salt and the sodium / ammonium polyaspartate repeating unit or the potassium / ammonium polyaspartate repeating unit is p:1, wherein 0.01≤p≤0.1.

[0019] Furthermore, the final product, the polyaspartate chelated zinc aqueous solution, has a soluble solid content of 5wt% to 30wt%.

[0020] Furthermore, the mass fraction of zinc in the soluble solid content is 0.01wt% to 5wt%, and the content of free zinc in the polyaspartic acid chelated zinc aqueous solution does not exceed 1% of the mass fraction of zinc.

[0021] Another aspect of the present invention provides a cosmetic composition, comprising the polyaspartate chelated zinc aqueous solution as described in any one of the above descriptions.

[0022] (III) Beneficial effects

[0023] The present invention provides a preparation method and application of polyaspartic acid chelated zinc. In the preparation method, sodium hydroxide or potassium hydroxide, ammonia water, and polysuccinimide are used to prepare a sodium polyaspartic acid / ammonium copolymer aqueous solution or a potassium polyaspartic acid / ammonium copolymer aqueous solution, and then an inorganic acid aqueous solution is added to adjust the pH of the above solution to 4.5-6.5, and then a water-soluble zinc salt is added, and the solution is continuously and fully stirred in a water bath at 60-80°C, and the obtained solution is filtered to obtain the final product polyaspartic acid chelated zinc aqueous solution. Compared with the production process using zinc oxide or zinc hydroxide as raw materials, the preparation method of the present invention uses water as a solvent for homogeneous reaction, and there is no acid-base neutralization exothermic process, the process is simple, the conditions are mild, and the cost difference is small. The polyaspartic acid chelated zinc obtained by the preparation method of the present invention has a chelation rate of more than 99% in terms of zinc element, and there are few free zinc ions, which is suitable for use as an effective ingredient in cosmetics. The polyaspartic acid chelated zinc prepared by the present invention is used in cosmetics, and can effectively exert the effects of polyaspartic acid chelated zinc in moisturizing, whitening, oil control, and anti-inflammatory. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 It is a schematic diagram of the molecular structure of polyaspartic acid chelated zinc of the present invention;

[0025] Figure 2 is a schematic diagram of the reaction process of step S1 in a specific embodiment of the present invention;

[0026] Figure 3 Schematic diagram of the reaction process of step S2 in a specific embodiment of the present invention;

[0027] Figure 4 This is the UV / visible full wavelength scanning spectrum of the product obtained in Example 6 of the present invention.

[0028] Figure 5 Infrared spectrum of the product obtained in Example 6 of the present invention;

[0029] Figure 6 Thermogravimetric analysis of the product obtained by the method of Example 6 of the present invention;

[0030] Figure Number:

[0031] 1. Zinc sulfate; 2. Zinc lactate; 3. Sodium polyaspartate; 4. Zinc polyaspartate chelate; 5. Sodium polyaspartate; 6. Zinc polyaspartate chelate; 7. Sodium TG-polyaspartate; 8. Zinc TG-polyaspartate chelate; 9. Sodium DTG-polyaspartate; 10. Zinc DTG-polyaspartate chelate. DETAILED DESCRIPTION

[0032] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with specific embodiments and with reference to the accompanying drawings. It should be understood that these descriptions are only exemplary and are not intended to limit the scope of the present invention. In addition, in the following description, the description of well-known structures and technologies is omitted to avoid unnecessary confusion of the concept of the present invention.

[0033] Where a numerical range is provided, it is understood that each intervening value between the upper and lower limits of the range and any other specified or intervening values ​​in the specified range is encompassed within the present invention. The upper and lower limits of these smaller ranges may be independently included in the smaller ranges and are also encompassed within the present invention, subject to any explicitly excluded limits in the specified ranges. Where a specified range includes one or two limits, ranges excluding either or both of those included limits are also encompassed within the present invention.

[0034] Any numerical value mentioned in the present invention includes all values ​​increasing by one unit each time from the lowest value to the highest value if there is only an interval of two units between any minimum value and any maximum value. For example, if the amount of a component, or the value of a process variable such as temperature or time is declared to be 3 to 40, in this specification it means that 4 to 39, 5 to 38 ... and 20 to 23 and 21 to 24 are specifically listed. For non-integer values, 0.1, 0.01, 0.001 or 0.0001 can be appropriately considered as a unit. These are just some specially specified examples. In this application, in a similar manner, all possible combinations of numerical values ​​between the listed lowest and highest values ​​are considered to have been disclosed.

[0035] Unless otherwise defined, all terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, preferred methods and materials are now described.

[0036] 1. Terminology

[0037] The term "water" used in the present invention, unless otherwise specified, refers to deionized water, ultrapure water or distilled water.

[0038] The terms "polyaspartic acid", "polyaspartic acid" and "polyaspartic acid" used in the present invention have the same meaning, and the terms "polyaspartate chelated zinc", "polycondensed aspartate chelated zinc" and "polyaspartate chelated zinc" can also be used interchangeably.

[0039] 2. Testing instruments and methods

[0040] In the present invention, the pH value is measured by SevenDirect SD20 of Mettler Toledo. The soluble solid content is measured by PAL-1 of ATAGO. The total zinc content and the free zinc ion content are measured by atomic absorption spectrophotometry and EDTA titration, respectively, according to group standard T / CFIAS6007-2024. The present invention uses a cell experiment to analyze and compare the efficacy of the polyaspartate chelated zinc. 3. Specific implementation methods

[0042] In one aspect, the present invention provides a method for preparing polyaspartic acid chelated zinc, comprising:

[0043] S1, dissolving sodium hydroxide or potassium hydroxide in deionized water, adding ammonia water dropwise and mixing thoroughly, adding polysuccinimide (PSI), continuing to stir and dissolve thoroughly, and filtering to obtain a polyaspartic acid sodium / ammonium copolymer (PASPNa / NH4) aqueous solution or a polyaspartic acid potassium / ammonium copolymer (PASPK / NH4) aqueous solution;

[0044] S2, using an inorganic acid aqueous solution, adjusting the pH of the PASPNa / NH4 aqueous solution or the PASPK / NH4 aqueous solution to 4.5-6.5, adding a water-soluble zinc salt, and continuing to fully stir in a water bath at 60-80° C. for 1-3 hours to obtain a product solution;

[0045] S3, separating and removing soluble impurities in the product solution to obtain a colorless or light yellow final product, polyaspartate chelated zinc aqueous solution.

[0046] Furthermore, in S1, the PSI is obtained by polymerization of aspartic acid, and the average molecular weight of the PSI is in the range of 3 to 50 kDa.

[0047] Furthermore, in S1, the molar ratio of the ammonia water (NH3 in ammonia water), the sodium hydroxide or potassium hydroxide, and the polysuccinimide repeating unit is x:1:y, wherein 0.05≤x≤0.2, 0.8≤y≤1, and the polysuccinimide is composed of polysuccinimide repeating units.

[0048] Furthermore, in S1, the PASPNa / NH4 or PASPK / NH4 aqueous solution may be diluted with deionized water or not, wherein the mass fraction of PASPNa / NH4 or PASPK / NH4 is 3wt% to 30wt%.

[0049] Furthermore, in S1, the mass ratio of the deionized water to the PSI is k:1, wherein 2.5≤k≤5.

[0050] Furthermore, the concentration of hydrogen ions in the inorganic acid aqueous solution is 1 mol / L, and the inorganic acid includes one or more of hydrochloric acid, sulfuric acid, phosphoric acid and nitric acid.

[0051] Further, in S2, the molar ratio between zinc, sodium polyaspartate / ammonium repeating units or potassium polyaspartate / ammonium repeating units in the water-soluble zinc salt is p:1, wherein 0.01≤p≤0.1, and the water-soluble zinc salt includes zinc chloride, zinc sulfate, zinc nitrate, zinc acetate, zinc lactate, zinc gluconate and zinc aspartate.

[0052] Furthermore, the final product, the polyaspartate chelated zinc aqueous solution, has a soluble solid content of 5wt% to 30wt%.

[0053] Furthermore, the mass fraction of zinc in the soluble solid content is 0.01wt% to 5wt%, and the free zinc content in the polyaspartic acid chelated zinc aqueous solution does not exceed 1% of the mass fraction of zinc. The molecular structure of the product polyaspartic acid chelated zinc is shown in Figure 1 , the reaction process of step S1 is shown in Figure 2 The reaction process of step S2 is shown in Figure 3 .

[0054] Furthermore, the method for separating and removing soluble impurities in the product solution in S3 includes membrane filtration and electrodialysis.

[0055] Another aspect of the present invention provides a cosmetic composition, comprising the polyaspartic acid chelated zinc aqueous solution as described in any one of the above claims, and the cosmetic composition is used to prepare facial masks, hand care products, sunscreen products, skin refreshing products, antifreeze products, anti-dandruff products, moisturizing products, anti-inflammatory products, whitening products and whitening and demelling products for pigmentation.

[0056] The above scheme is described in detail below in conjunction with specific embodiments. Specific experimental methods not mentioned in the following examples are usually carried out according to conventional experimental methods. The raw materials or components used in the present invention can be obtained through commercial channels or conventional methods unless otherwise specified.

[0057] Example 1 Preparation of polyaspartate chelated zinc

[0058] Accurately weighed deionized water was added to a 50 mL beaker, and then accurately weighed NaOH was added thereto; after sufficient stirring to completely dissolve the NaOH, accurately weighed ammonia water was added, and stirred and mixed evenly at room temperature; then accurately weighed PSI was added to the above mixed solution, stirred and reacted at room temperature for 2 h, and then the insoluble matter was removed by suction to obtain a PASPNa / NH4 aqueous solution.

[0059] After adjusting the pH of the PASPNa / NH4 aqueous solution with 1 mol / L hydrochloric acid aqueous solution, accurately weighed zinc salt was added; then the mixture was stirred for 3 hours in a 60°C water bath to obtain a light yellow solution. The light yellow solution was separated by filtration through a filter membrane with a molecular weight cutoff of 3 kDa (deionized water was used to make up for the loss of the reaction system based on the mass of the filtrate) to obtain a polyaspartic acid chelated zinc solution. The specific process parameters and product indicators in the above process are shown in Tables 1 and 2 (replace NaOH in Example 1 with KOH, and the steps and calculation processes are the same).

[0060] In addition, the preparation process of Examples 2-19 is the same as that of Example 1. The specific process parameters of each are shown in Table 1. Table 2 is the product test results corresponding to each example in Table 1.

[0061] Table 1 Preparation process parameters of polyaspartate chelated zinc

[0062]

[0063]

[0064] Table 2 Test results of each embodiment

[0065]

[0066] As shown in Table 2, membrane filtration can more thoroughly remove free zinc ions that have not formed a chelated structure.

[0067] In combination with Table 1 and Table 2, by comparing Example 1, Example 6 and Example 19, it can be seen that the average molecular weight of the raw material polysuccinimide PSI (PSI molecular weight for short) will affect the soluble solids and zinc content of the product, that is, the lower the molecular weight of the PSI preparation process, the higher the content of small molecules, the more soluble solids are lost after the filter membrane, and the zinc content chelated with PASP is also lost, see Example 1 (this principle involves the production process of PSI. In the production of PSI, temperature, time, and catalyst dosage will affect the molecular weight of the product PSI. Among them, low temperature, short time, and small amount of catalyst will make the product PSI molecular weight low, but at the same time it will make the reaction rate low, that is, more small molecules; vice versa, the production process of PSI has been publicly reported); and when the PSI molecular weight is too high, due to the steric hindrance of the molecular chain entanglement, the chelate structure formed is relatively less, see Example 19. The average molecular weight range of PSI in the present invention is 3 to 50 kDa, preferably 20 kDa, see Example 6.

[0068] Combining Examples 2 and 4 with Examples 3 and 5, it can be seen that the amount of NaOH added within an appropriate range has little effect on the soluble solids and zinc content of the product, but too little NaOH (Example 3) will cause incomplete hydrolysis of PSI to form insoluble matter and reduce the soluble solids content, while too much NaOH added (Example 2) will increase the processing pressure of membrane filtration.

[0069] Combining Experimental Examples 4, 5, and 6, it can be seen that the increase of ammonia can increase the content of PASN in the polymer, which is beneficial to the formation of chelated zinc structure within a suitable range. However, excessive addition of ammonia (Example 5) will cause the pH to drop during the hydrolysis of PSI to form insoluble matter, and the soluble solid content will decrease.

[0070] From the above comparison, it can be seen that the molar ratio of the repeating unit formed by the ammonia water (NH3 in the ammonia water), the sodium hydroxide or potassium hydroxide, and the polysuccinimide is x:1:y (0.05-0.2:1:0.8-1), wherein 0.05≤x≤0.2, 0.8≤y≤1. The following example 6 is used to illustrate the molar relationship between the ammonia water, sodium hydroxide and PSI repeating unit, and the calculation process is as follows:

[0071] The concentration of ammonia water is 25%, and the molecular weight of ammonia water is 35, so the molar amount of ammonia water (in terms of NH3H2O) is 52.87×0.25 / 35=0.3776 mol;

[0072] The molar amount of sodium hydroxide is: 137.46 / 40=3.4365 mol;

[0073] The molar weight of the PSI repeating unit is: the molecular weight of aspartic acid is 133, and the PSI repeating unit is the product of removing 2 molecules of water from aspartic acid, and its molecular weight is 97. Therefore, the molar weight of PSI is 300 / 97=3.0928 mol;

[0074] Therefore, the molar ratio of ammonia water, sodium hydroxide and PSI repeating unit is 0.11:1:0.89; the calculation process of other embodiments is similar.

[0075] In combination with Examples 6 to 9, it can be seen that as the amount of zinc salt added increases within a suitable range, the zinc content of the product will increase accordingly; however, due to the limited number of chelated zinc structures that the PASP / PASN system can accommodate, the zinc salt cannot be increased indefinitely, and the excess zinc salt cannot be chelated and exists in a free state and is removed by membrane filtration. The far excess zinc salt will also form insoluble matter, see Example 9 (Example 9 is a high limit for the amount of zinc salt added. This example proves that after the amount of zinc salt added reaches a certain level, increasing the amount of zinc salt added does not increase the amount of chelated zinc. Instead, the excess zinc will be in the form of free zinc and removed during the membrane filtration process).

[0076] Combined with Examples 6, 10 to 15, it can be seen that since PASP has strong chelating properties, generally soluble zinc salts can form chelate structures with PASP / PASN; in zinc salts, factors such as whether the anion is organic or inorganic, the size of the anion, and the solubility of the zinc salt will have some influence on the zinc content, but the influence is not significant. The molar ratio of zinc in the water-soluble zinc salt, the repeating unit in PASPNa / NH4 or the repeating unit in PASPK / NH4 is p:1, where 0.01≤p≤0.1, and the molar amount of the repeating unit in PASPNa / NH4 or PASPK / NH4 is equal to the molar amount of the repeating unit in PSI, and the principle is: polysuccinimide is hydrolyzed under alkaline conditions to obtain polyaspartate. That is, polysuccinimide is hydrolyzed in an aqueous sodium hydroxide solution to obtain sodium polyaspartate; the same is true for potassium hydroxide. Therefore, the repeating unit of polysuccinimide is succinimide, and the repeating unit of sodium polyaspartate is aspartic acid. For the same polymer chain (i.e., polymer molecule), the number of repeating units of polysuccinimide and sodium polyaspartate remains unchanged before and after hydrolysis; that is, although the polymer undergoes structural changes before and after hydrolysis, the molar number of repeating units remains unchanged. Therefore, the "molar ratio between zinc, sodium polyaspartate / ammonium repeating units, or potassium polyaspartate / ammonium repeating units" is equal to the "molar ratio between zinc and PSI repeating units."

[0077] Example 6 is used to illustrate the molar relationship of zinc (Zn) and PASPNa / NH4 repeating units as follows:

[0078] The molecular weight of zinc sulfate is generally calculated as 161, so the molar weight is 17.43 / 161=0.1083 mol.

[0079] The molar ratio of Zn to PASPNa / NH4 repeating units is 0.1083:3.0928, i.e., 0.035:1. The calculation process of other embodiments is similar.

[0080] Combining Examples 6 and 16, it can be seen that increasing the amount of water added and reducing the concentration of the reaction system not only inevitably reduces the soluble solids, but also significantly reduces the zinc content. The mass ratio of the deionized water to the polysuccinimide is k:1, where 2.5≤k≤5.

[0081] Taking Example 6 as an example, the amount of water added is 860.3 mL (based on the density of deionized water being 1.0 g / mL, the amount added is 860.3 g), and its mass ratio to PSI is 2.87:1. The calculation process of other examples is similar.

[0082] In addition, in combination with Examples 6, 17, and 18, it can be seen that the pH of the reaction system has a great influence on the zinc content. Too large (Example 18) or too small pH (Example 17) values ​​will significantly reduce the zinc content in the product. From the results, the pH value is the most important influencing factor, and it is finally determined that the pH is adjusted to 4.5-6.5.

[0083] The mass fraction of PASPNa / NH4 formed in S1 of the present invention is 3wt% to 30wt% (if NaOH is replaced by KOH, the mass fraction of PASPK / NH4 is 3wt% to 30wt%). Taking Example 6 as an example, the calculation process of the mass fraction of PASPNa / NH4 is:

[0084] The molecular weight of the PASPNa / NH4 repeating unit is 96, the molar number of the PASPNa / NH4 repeating unit is also 3.0928 mol, and the mass of water is 860.3 g.

[0085] PASPNa / NH4 mass fraction = 96 × 3.0928 / (96 × 3.0928 + 860.3) ×

[0086] 100%=25.7wt%, the calculations for other embodiments are similar.

[0087] The polyaspartate chelated zinc aqueous solution prepared by the present invention has a soluble solid content of 5wt% to 30wt%, preferably 5wt% to 25wt%;

[0088] The mass fraction of zinc in the soluble solid content is 0.01wt% to 5wt%, preferably 0.05wt% to 1wt%;

[0089] The free zinc content in the polyaspartate chelated zinc aqueous solution does not exceed 1% of the mass fraction of zinc.

[0090] The polyaspartic acid chelated zinc obtained by the preparation method of the present invention has a chelation rate of more than 99% based on zinc element, few free zinc ions, simple process, mild conditions and small cost difference.

[0091] The product of Example 6 was subjected to UV / visible full wavelength scanning, infrared and thermogravimetric analysis, and the results were as follows: Figure 4 , Figure 5 and Figure 6 Among them, Figure 4 The results of the full-wavelength ultraviolet / visible light scanning show that (the upper right corner is an ultraviolet magnified image of polyaspartic acid chelated zinc and sodium polyaspartate), relative to the maximum absorption peak of sodium polyaspartate at 230nm (label 3), polyaspartic acid chelated zinc (label 4) has an additional absorption peak of 219nm. It can be seen from this figure that sodium polyaspartate alone has one and only one maximum absorption peak at an ultraviolet wavelength of about 230nm; and the product of the present invention has a chelated zinc structure in addition to sodium polyaspartate, and the chelated structure has an ultraviolet absorption peak at an ultraviolet wavelength of 219nm. Therefore, the ultraviolet full-wavelength scanning spectrum can qualitatively prove that the present invention obtains a new compound different from the original sodium / ammonium polyaspartate through a chelation reaction, and it is determined to be polyaspartic acid chelated zinc according to the reaction conditions). Figure 4 The horizontal axis is wavelength (Wavelength), in nm, and the vertical axis is absorbance (ABs). The changes in the vibration peaks on the infrared spectrum are shown in Table 3. The stretching vibration peaks of the acyl and amino groups in the infrared spectrum of the amide bonds on the main chain of polyaspartic acid and the carboxyl groups on the side chains will inevitably cause changes in the absorption peak positions after chelating with zinc ions. Figure 5 As shown in Table 3, the infrared spectra of polyaspartic acid chelated zinc (label 6) and polyaspartic acid sodium (label 5) are compared. It is found that after the chelation reaction, the C=O stretching vibration peak shifts and splits into two peaks. The CO stretching vibration peak is obviously red-shifted. Although the absorption peak representing COOH does not shift much, its intensity is significantly weakened, which indicates that a large number of carboxyl groups participate in the chelation structure; the absorption peaks of NH, CH, and CN bonds also shift to varying degrees, indicating that the zinc atom and polyaspartic acid form a chelate structure and affect the stretching vibration of the chemical bonds of its surrounding groups. Figure 4 The UV full wavelength scanning spectrum is similar to that of Figure 5 The infrared spectrum of is also a qualitative analysis of the polyaspartic acid chelate structure. That is, compared with sodium polyaspartate, the vibration peak position associated with the carboxyl group shifts, indicating that the carboxyl group participates in the zinc chelate structure, and at the same time qualitatively proves the formation of the chelated zinc structure. Figure 5 The horizontal axis is the wave number (Wavenumber), the unit is cm -1 , the vertical axis is transmittance.

[0092] Table 3 Changes of vibration peaks in infrared spectra

[0093]

[0094] from Figure 6 It can be seen from the thermogravimetric analysis that during the continuous heating process, sodium polyaspartate (see curve 7) will first slowly decrease in mass at 100°C to 300°C as bound water evaporates, and then sharply decrease in mass at around 300°C as the side chain carboxyl groups decarboxylate and dehydrate. At around 400°C, the amide bond breaks, the carbon chain rearranges, and small molecules such as CO2, H2O, and NH3 are released, resulting in a decrease in mass. Zinc chelate polyaspartate has a chelate structure (see curve 8), which is similar to a cross-linking agent and can appropriately improve the thermal stability of the polymer. Therefore, the mass loss of zinc chelate polyaspartate at around 300°C is lower than that of sodium polyaspartate, and at around 350°C, a mass loss stage will increase as the chelate structure disintegrates and is accompanied by decarboxylation and dehydration. Figure 6 TG is a thermogravimetric curve, and DTG is a differential thermogravimetric curve. The thermogravimetric analysis results of this figure prove that the mass loss degree and loss rate of the product of the present invention and sodium polyaspartate are different during the continuous increase in temperature; that is, the present invention has obvious structural differences compared with the sodium / ammonium polyaspartate of the raw material.

[0095] Based on the results of ultraviolet, infrared and thermogravimetric analysis, it can be qualitatively concluded that the product of the present invention has a new structure that is significantly different from the original sodium / ammonium polyaspartate; and, judging from the reaction process, a relatively stable chelated zinc structure exists in the product of the present invention.

[0096] 4. Preparation process scale-up

[0097] Based on the process conditions of Example 6 above, industrial preparation of polyaspartic acid chelated zinc was carried out. The specific method is: 34.4L deionized water was added to a 70L reaction tank, 5.50kg NaOH was slowly added thereto under stirring, and 2.12kg ammonia water was added after complete dissolution and fully stirred and mixed. After the mixed solution returned to room temperature, 12kg PSI was slowly added under stirring and continued to stir for 2h to obtain a PASPNa / NH4 aqueous solution. After the above PASPNa / NH4 aqueous solution was filtered through a pipeline filter to remove insoluble matter, the pH was adjusted to 6.0 with a 1mol / L hydrochloric acid aqueous solution, and then 0.70kg zinc sulfate was slowly added. After the addition of zinc sulfate was completed, the reaction tank was heated to 60°C and fully stirred for 3h. After the reaction was completed, the system was naturally cooled to room temperature, and the product polyaspartic acid chelated zinc solution was obtained by filtering through a 3000 filter membrane (the loss of the reaction system was supplemented with deionized water based on the mass of the filtrate). The product was light yellow in color and weighed 49.84 kg in total. The soluble solid content was 24.44 wt %, the total zinc content was 0.47 wt %, and no free zinc was detected.

[0098] It can be seen from the enlarged experiment that the preparation process of the present invention has the conditions for industrial production.

[0099] 5. Efficacy Evaluation

[0100] 1. Evaluation of anti-inflammatory efficacy (hyaluronidase inhibition rate)

[0101] Hyaluronidase is a participant in type I allergic reactions. Hyaluronidase is strongly correlated with inflammation and allergy. Studies have reported that various drugs that release histamine from mast cells can regulate hyaluronidase activity. Some anti-allergic drugs have strong inhibitory effects on hyaluronidase activity. Therefore, the inhibition of hyaluronidase activity is used as an indicator for studying anti-inflammatory effects.

[0102] The polyaspartic acid chelated zinc prepared by the present invention is tested for hyaluronidase inhibition rate, and the testing method includes:

[0103] (1) Prepare the test solution according to the composition shown in Table 4.

[0104] Table 4 Composition of the solution to be tested

[0105]

[0106] (2) After keeping the solutions obtained in step (1) at 37°C for 20 min, 0.1 mL of 2.5 mol / L CaCl2 solution was added dropwise to each solution; after keeping the solution at 37°C for another 20 min, 0.5 mL of 0.5 mg / ml sodium hyaluronate solution was added dropwise to solution A and solution C, and 0.5 mL of pH 5.6 acetate buffer solution was added dropwise to solution B and solution D, respectively.

[0107] (3) After the solutions obtained in the above step (2) were kept at 37°C for 40 minutes, they were placed at room temperature (25°C) for 10 minutes, and 0.5 mL of pure water and 0.1 mL of 5 mol / L NaOH solution were added dropwise respectively; at the same time, 0.5 mL of the mixed solution was also added dropwise. The mixed solution was prepared by mixing 50 mL of 10 mol / L sodium carbonate solution and 3.5 mL of acetylacetone to form a mixed solution.

[0108] (4) The solutions obtained in step (3) were placed in a boiling water bath for 15 min, then in an ice bath for 10 min, and then allowed to stand at room temperature (25°C) for 10 min; 0.8 g of p-dimethylaminobenzaldehyde was dissolved in 15 ml of concentrated hydrochloric acid and 15 ml of anhydrous ethanol to prepare a P-DAB color developer; 1 mL of the P-DAB color developer was added dropwise to each of the solutions obtained in step (3).

[0109] (5) After the solution obtained in step (4) is fully shaken, the volume of the solution is supplemented to 8 mL with anhydrous ethanol; after standing at room temperature (25° C.) for 30 min, the absorbance at 530 nm is detected using an ultraviolet spectrophotometer.

[0110] The calculation method of hyaluronidase inhibition rate is:

[0111]

[0112] Wherein: A is the ultraviolet absorption value of solution A (i.e., a mixed solution of sample, hyaluronidase and sodium hyaluronate); B is the ultraviolet absorption value of solution B (i.e., a mixed solution of sample and acetate buffer); C is the ultraviolet absorption value of solution C (i.e., a mixed solution of hyaluronidase and sodium hyaluronate); and D is the ultraviolet absorption value of solution D (i.e., acetic acid buffer).

[0113] The hyaluronidase inhibition rate was detected according to the above method, using the products obtained in Examples 6, 7, 9, and 13 diluted 20 times as samples, 1wt% sodium polyaspartate (molecular weight 8 kDa) aqueous solution and 2.48wt% zinc sulfate aqueous solution as controls, and acetate buffer as blank. The results are shown in Table 5.

[0114] Table 5 Hyaluronidase inhibition rate test results

[0115]

[0116] As shown in Table 5, each sample solution has a hyaluronidase inhibitory effect. Among them, with the increase of chelated zinc content, the hyaluronidase inhibition rate shows an upward trend, but there is no linear relationship between the two; when the zinc content is increased to a limit, the increase in the hyaluronidase inhibition rate will slow down. At the same time, the hyaluronidase inhibition rate is not greatly affected by the type of zinc salt added in the process. In addition, the hyaluronidase inhibition rate of polyaspartic acid chelated zinc is significantly higher than that of sodium polyaspartate, indicating that the zinc element has a significant promoting effect therein; and the hyaluronidase inhibition rate of chelated zinc is higher than that of free zinc ions, indicating that the chelated structure can improve the utilization rate of the zinc element. As can be seen from the above, polyaspartic acid chelated zinc has a significant effect on the improvement of the hyaluronidase inhibition rate and has good anti-inflammatory effects.

[0117] 2. Whitening efficacy evaluation (tyrosinase inhibition rate)

[0118] Tyrosinase is the rate-limiting enzyme in the process of melanin synthesis. The depth of human epidermal pigment and pigmentation diseases are all related to the activity of tyrosinase in the body. The greater the activity, the higher the content, and the easier it is to form melanin. In the metabolic process, L-tyrosine can generate dopa under the action of tyrosinase, and dopa will generate dopaquinone under the further catalysis of tyrosinase. Since dopaquinone has a maximum absorption peak at a wavelength of 475nm, the absorbance of the product dopaquinone can be measured to characterize the inhibition efficiency of the sample on tyrosine and prove its whitening effect.

[0119] The testing methods for the whitening effect of polyaspartate chelated zinc include:

[0120] (1) Prepare the test solution according to the composition shown in Table 6.

[0121] Table 6 Ratio of solution to be tested

[0122]

[0123] (2) After heating each solution in a 37°C water bath for 10 min, the absorbance at 475 nm was measured using an ultraviolet spectrophotometer.

[0124] The calculation method of tyrosinase inhibition rate is:

[0125]

[0126] Wherein: C1 is the absorbance of tyrosine solution; C2 is the absorbance of the mixed solution of tyrosinase and tyrosine; T1 is the absorbance of the sample to be tested and the tyrosine solution; T2 is the absorbance of the mixed solution of the sample to be tested, tyrosinase and tyrosine.

[0127] The tyrosinase inhibition rate was detected according to the above method, using the products obtained in Examples 6, 7, 9, and 13 diluted 20 times as samples, 1wt% aqueous solution of sodium polyaspartate (molecular weight 8 kDa) and 2.48wt% aqueous solution of zinc sulfate as controls, and phosphate buffer as blank. The results are shown in Table 7.

[0128] Table 7 Tyrosinase inhibition rate

[0129]

[0130] As shown in Table 7, each sample solution has a tyrosinase inhibitory effect, and is similar to the above-mentioned hyaluronidase inhibition rule. Among them, with the increase of chelated zinc content, the tyrosinase inhibition rate shows an upward trend, but there is no linear relationship between the two; when the zinc content is increased to a limit, the increase in tyrosinase inhibition rate will slow down. At the same time, the tyrosinase inhibition rate is not greatly affected by the type of zinc salt added in the process. In addition, the tyrosinase inhibition rate of polyaspartic acid chelated zinc is significantly higher than that of sodium polyaspartate, indicating that the zinc element has a significant promoting effect therein; and the tyrosinase inhibition rate of chelated zinc is higher than that of free zinc ions, indicating that the chelated structure can improve the utilization rate of zinc. From the above, it can be seen that polyaspartic acid chelated zinc has a significant effect on improving the tyrosinase inhibition rate and has a good whitening effect.

[0131] 3. Evaluation of oil control efficacy (5α-reductase inhibition rate)

[0132] 5α-reductase is a membrane protease that depends on reduced coenzyme II (NADPH). It is an important male hormone metabolic enzyme in the skin. It can irreversibly convert testosterone into dihydrotestosterone. Dihydrotestosterone is the most active male hormone and can induce excessive oil secretion by sebaceous glands. Reducing dihydrotestosterone levels by inhibiting 5α-reductase activity can effectively alleviate excessive oil secretion by sebaceous glands. Therefore, inhibiting 5α-reductase activity is used as an indicator to study oil control effects.

[0133] The test methods for the inhibition rate of polyaspartate chelated zinc 5α-reductase include:

[0134] (1) Take out the Omnimabs Human Steroid 5 Alpha Reductase (SRD5a) kit and place it at room temperature (20-25°C) for 30 minutes.

[0135] (2) Strictly follow the operating procedures of the kit and finally measure the UV absorbance at 450nm.

[0136] (3) The 5α-reductase content was obtained according to the standard curve, and the 5α-reductase inhibition rate was calculated.

[0137] The 5α-reductase inhibition rate was calculated as follows:

[0138]

[0139] Wherein: C is the 5α-reductase content of the negative control; T is the 5α-reductase content of the sample solution.

[0140] The tyrosinase inhibition rate was detected according to the above method, using the products obtained in Experiments 6, 7, 9, and 13 in Example 1 diluted 20 times as samples, 1wt% aqueous solution of sodium polyaspartate (molecular weight 8 kDa) and 2.48wt% aqueous solution of zinc sulfate as controls, deionized water as a negative control, and 0.5μmol dutasteride as a positive control. The results are shown in Table 8.

[0141] Table 8 5α-reductase inhibition rate

[0142]

[0143] As shown in Table 8, each sample solution has an inhibitory effect on 5α-reductase, and is similar to the above-mentioned hyaluronidase inhibition rule. Among them, with the increase of chelated zinc content, the 5α-reductase inhibition rate shows an upward trend, but there is no linear relationship between the two; when the zinc content is increased to a limit, the increase in the 5α-reductase inhibition rate will slow down. At the same time, the tyrosinase inhibition rate is not greatly affected by the type of zinc salt added in the process. In addition, the tyrosinase inhibition rate of polyaspartic acid chelated zinc is significantly higher than that of sodium polyaspartate, indicating that zinc has a significant promoting effect in it; and the tyrosinase inhibition rate of chelated zinc is higher than that of free zinc ions, indicating that the chelated structure can improve the utilization rate of zinc. From the above, it can be seen that polyaspartic acid chelated zinc has a significant effect on improving the inhibition rate of 5α-reductase and has a good oil control effect.

Claims

1. A method for preparing polyaspartic acid chelated zinc, characterized in that: include: S1, dissolving sodium hydroxide or potassium hydroxide in deionized water, adding aqueous ammonia dropwise and mixing thoroughly, adding polysuccinimide, stirring to dissolve, and filtering to obtain a sodium polyaspartate / ammonium copolymer aqueous solution or a potassium polyaspartate / ammonium copolymer aqueous solution; S2, using an inorganic acid aqueous solution to adjust the pH of the sodium polyaspartate / ammonium copolymer aqueous solution or the potassium polyaspartate / ammonium copolymer aqueous solution to 4.5-6.5, adding a water-soluble zinc salt, and continuing to fully stir in a water bath at 60-80° C. to obtain a product solution; S3, separating and removing soluble impurities in the product solution to obtain a final product, a polyaspartate chelated zinc aqueous solution.

2. The method for preparing polyaspartate chelated zinc according to claim 1, characterized in that: In S1, the polysuccinimide is obtained by polymerization of aspartic acid, and the average molecular weight of the polysuccinimide is in the range of 3 to 50 kDa.

3. The method for preparing polyaspartate chelated zinc according to claim 1, characterized in that: In S1, the molar ratio of the ammonia water, the sodium hydroxide or potassium hydroxide, and the repeating unit of the polysuccinimide is x:1:y, wherein 0.05≤x≤0.2, 0.8≤y≤1, and the polysuccinimide is composed of the repeating units of polysuccinimide.

4. The method for preparing polyaspartate chelated zinc according to claim 1, characterized in that: In S1, the mass fraction of the sodium polyaspartate / ammonium copolymer aqueous solution or the potassium polyaspartate / ammonium copolymer aqueous solution is 3 wt % to 30 wt %.

5. The method for preparing polyaspartate chelated zinc according to claim 1, characterized in that: The method for separating and removing soluble impurities in the product solution in S3 includes membrane filtration and electrodialysis.

6. The method for preparing polyaspartate chelated zinc according to claim 1, characterized in that: The water-soluble zinc salts include zinc chloride, zinc sulfate, zinc nitrate, zinc acetate, zinc lactate, zinc gluconate and zinc aspartate.

7. The method for preparing polyaspartate chelated zinc according to claim 1, characterized in that: In S2, the molar ratio between zinc in the water-soluble zinc salt and the sodium / ammonium polyaspartate repeating unit or the potassium / ammonium polyaspartate repeating unit is p:1, wherein 0.01≤p≤0.

1.

8. The method for preparing polyaspartate chelated zinc according to claim 1, characterized in that: The final product, the polyaspartate chelated zinc aqueous solution, has a soluble solid content of 5wt% to 30wt%.

9. The method for preparing polyaspartate chelated zinc according to claim 8, characterized in that: The mass fraction of zinc in the soluble solid content is 0.01wt% to 5wt%, and the content of free zinc in the polyaspartic acid chelated zinc aqueous solution does not exceed 1% of the mass fraction of zinc.

10. A cosmetic composition, characterized in that The cosmetic composition comprises the polyaspartate chelated zinc aqueous solution according to any one of claims 1 to 9.

Citation Information

Patent Citations

  • Preparation method of polyaspartic acid divalent metal chelate salt

    CN115449075A

  • Artificial particle and its production

    JP1997132649A

  • Production of antibacterial metal salt of polyaspartic acid

    JP1997309952A